Ilana Reinhold, Rosanne Sprute, Jannik Stemler, Oliver A. Cornely
6 min
Invasive fungal infections, such as candidemia and invasive aspergillosis, are associated with high mortality rates in immunocompromised and critically ill patients. Historically, clinical management has been dictated by rigid, tradition-based protocols, such as the standard 14-day treatment course for candidemia and multi-month regimens for invasive mould infections. The authors argue that this "safe-default" approach, while intended to prevent relapse, often leads to unnecessary antifungal toxicity, disruption of the mycobiome, and increased healthcare costs without clear evidence of superior patient outcomes.
For candidemia, the 14-day treatment duration is increasingly being questioned. Observational data suggest that shorter courses may be equally effective for uncomplicated cases. To address this, several randomized controlled trials (such as CANDISHORT, SCAT, and CanTEN) are currently underway to determine if 7- or 10-day regimens provide non-inferior outcomes compared to the traditional 14-day standard. Similarly, for invasive mould infections, the authors advocate for moving away from fixed durations toward response-guided cessation, utilizing tools like PET-CT imaging, novel biomarkers, and host immune phenotyping to determine when it is safe to stop therapy.
Beyond duration, the authors highlight a persistent bias toward intravenous (IV) antifungal administration. Drawing parallels to recent advancements in bacterial infection management—where early switches to oral therapy have been validated—the authors suggest that many patients with invasive fungal infections could safely transition to oral triazoles once clinically stable. While concerns regarding bioavailability and the severity of illness persist, the emergence of new oral agents and better diagnostic monitoring could facilitate a broader adoption of oral-first strategies, improving patient autonomy and reducing the complications associated with long-term vascular access.
Sam: So if we're not using a calendar to decide when to stop, what are we using instead?
Alex: The paper proposes using a combination of clinical stability, symptom resolution, and advanced imaging. One example they highlight is the PET-CT scan. Here's how it works: a PET-CT can detect whether a spot in the lung — say, a shadow that showed up during the infection — is still an active problem, or just a harmless scar left over from the fight.
Sam: How does a scan tell the difference between a scar and an active infection?
Alex: It detects metabolic activity — essentially whether something is still consuming energy and "breathing." A scar is quiet. An active infection is not. So the scan tells you whether the fire is truly out, or just smoldering under the ashes.
Sam: That's a much more precise signal than just counting days on a calendar.
Alex: Exactly. And that precision matters, because it means you could stop treatment the moment the fungal burden is actually cleared — not a week later, just to be safe.
Sam: You also mentioned something about an "oral switch" — patients moving from hospital drips to pills. Is that part of this shift toward more flexible care?
Alex: It is. Many patients currently spend weeks in hospital on intravenous drips. But many antifungal drugs — particularly a class called the triazoles — are absorbed very efficiently when taken as a pill. A high percentage of the medicine gets into the bloodstream and does its job, almost as well as the IV version.
Sam: So if the pill works just as well, why keep the patient in the hospital at all?
Alex: That's exactly the question the authors are pushing. Keeping someone in hospital for an IV line carries its own risks — catching other infections, losing mobility, the general toll of a long hospital stay. If the pill is equally effective, getting people home sooner is genuinely better care, not just more convenient.
Sam: Are there major roadblocks to making this the new standard?
Alex: The biggest one is the lack of large-scale, randomized controlled trials — the kind of rigorous study where you randomly assign patients to different treatments and carefully compare outcomes. That's considered the gold standard of medical evidence. Right now, we have strong theoretical reasoning and some promising early data, but the field is still waiting for that definitive proof.
Sam: So the theory is sound, but we need the hard evidence before this becomes routine practice?
Alex: That's the situation. There are currently several major trials underway testing whether shorter courses — around seven to ten days — are as effective as the standard fourteen. The results will be significant for how the field moves forward.
Sam: It's striking how much of medicine is built on "that's how we've always done it" — and how much effort it takes to replace that with something better measured.
Alex: It's a common pattern. Science tends to move slowly, replacing old habits with new evidence one careful study at a time. But when the evidence arrives, it can meaningfully change how patients are treated — and in this case, potentially spare them weeks of unnecessary treatment.
Sam: This has been a clear look at why rethinking these treatment schedules matters. Thanks for walking through the logic.
Alex: It was a pleasure. It's a meaningful area of research, and the upcoming trials should tell us a great deal. Thanks for listening to ResearchPod.